A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation

Antonio E. Muruato, Camila R. Fontes-Garfias, Ping Ren, Mariano A. Garcia-Blanco, Vineet D. Menachery, Xuping Xie, Pei Yong Shi

Research output: Contribution to journalArticle

Abstract

Virus neutralization remains the gold standard for determining antibody efficacy. Therefore, a high-throughput assay to measure SARS-CoV-2 neutralizing antibodies is urgently needed for COVID-19 serodiagnosis, convalescent plasma therapy, and vaccine development. Here, we report on a fluorescence-based SARS-CoV-2 neutralization assay that detects SARS-CoV-2 neutralizing antibodies in COVID-19 patient specimens and yields comparable results to plaque reduction neutralizing assay, the gold standard of serological testing. The fluorescence-based neutralization assay is specific to measure COVID-19 neutralizing antibodies without cross reacting with patient specimens with other viral, bacterial, or parasitic infections. Collectively, our approach offers a rapid platform that can be scaled to screen people for antibody protection from COVID-19, a key parameter necessary to safely reopen local communities.

Original languageEnglish (US)
Article number4059
JournalNature communications
Volume11
Issue number1
DOIs
StatePublished - Dec 1 2020

ASJC Scopus subject areas

  • Chemistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Physics and Astronomy(all)

Fingerprint Dive into the research topics of 'A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation'. Together they form a unique fingerprint.

  • Cite this